Stock Fundamentals

Company Information

Company Name
Cue Biopharma
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US22978P1066
CIK: 0001645460
CUSIP: 22978P106
Currency: USD
Full Time Employees: 29
Phone: 617 949 2680
Fiscal Year End: December
IPO Date: Jan 02, 2018
Description:

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Address:

40 Guest Street, Boston, MA, United States, 02135

Directors & Officers

Name Title Year Born
Ms. Lucinda Warren Principal Fin & Accounting Off. and Chief Financial & Business Officer 1969
Mr. Colin G. Sandercock J.D., MSE Senior Vice President of Intellectual Property 1957
Dr. Shao-Lee Lin M.D., Ph.D. President, CEO & Director 1967
Dr. Ronald D. Seidel III, Ph.D. Co-Founder 1976
Dr. Rodolfo Jose Chaparro Ph.D. Co-Founder 1973
Dr. Steven C. Almo Ph.D. Co-Founder and Chairman of Scientific & Clinical Advisory Board 1961
Ms. Sumita Ray J.D. Chief Legal & Compliance Officer and Corporate Secretary 1974
Dr. Daniel G. Baker M.D., Ph.D. Interim Chief Development Officer 1950

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 16, 2024 Daniel R Passeri N/A Purchase 1.00K $30.90 $30.90K
Aug 25, 2023 Anish Suri N/A Purchase 133.00 $82.80 $11.01K
Aug 14, 2023 Daniel R Passeri N/A Purchase 100.00 $85.80 $8.58K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Bleichroeder LP 6.82M Mar 31, 2026 5.62% $0.27 0.00%
Catalytic Wealth RIA LLC 4.63M Mar 31, 2026 3.82% $0.04 0.00%
Vanguard Group Inc 3.01M Dec 31, 2025 2.48% $0.00 -0.83%
Vanguard Capital Management, LLC 2.46M Mar 31, 2026 2.02% $0.00 0.00%
Lion Point Capital, LP 2.20M Mar 31, 2026 1.82% $3.03 0.00%
Geode Capital Management, LLC 1.06M Mar 31, 2026 0.88% $0.00 32.54%
Vanguard Fiduciary Trust Co 543.59K Mar 31, 2026 0.45% $0.00 0.00%
Robertson Stephens Wealth Management, LLC 478.50K Mar 31, 2026 0.39% $0.00 0.00%
BlackRock Inc 449.16K Mar 31, 2026 0.37% $0.00 0.00%
Texas Capital Bank Wealth Management Services Inc 397.42K Mar 31, 2026 0.33% $0.01 -9.81%
ANGELES WEALTH MANAGEMENT, LLC 310.00K Mar 31, 2026 0.26% $0.00 0.00%
Advisory Research Inc 257.23K Mar 31, 2026 0.21% $0.01 0.00%
Stifel Financial Corp 246.56K Mar 31, 2026 0.20% $0.00 0.00%
Renaissance Technologies Corp 213.83K Mar 31, 2026 0.18% $0.00 -10.29%
Bank of America Corp 207.71K Mar 31, 2026 0.17% $0.00 0.07%
State Street Corp 179.35K Mar 31, 2026 0.15% $0.00 0.00%
Diadema Partners LP 132.00K Mar 31, 2026 0.11% $0.01 0.00%
Northern Trust Corp 94.61K Mar 31, 2026 0.08% $0.00 -6.29%
UBS Group AG 88.35K Mar 31, 2026 0.07% $0.00 88.59%
Chicago Partners Investment Group LLC 85.94K Mar 31, 2026 0.07% $0.00 0.00%

Shares Statistics

Shares Outstanding: 4.20M
Shares Float: 3.64M
% Insiders: 855.00%
% Institutions: 1,770.60%
Short % Float: 7.13%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Extended Equity Market Fund E 118.45K 0.12% ▲ 0.00% Dec 31, 2025
2 Extended Equity Market Fund B 118.45K 0.12% ▲ 0.00% Dec 31, 2025
3 BlackRock Extended Equity Market Fund K 100.85K 0.10% ▼ 0.73% Mar 31, 2026
4 Vanguard Total Stock Mkt Idx Inv 93.37K 2.90% ▼ 93.86% Apr 30, 2026
5 NT Ext Equity Mkt Index Fund - Lending 71.99K 0.07% ▲ 0.00% Mar 31, 2026
6 Vanguard Institutional Extnd Mkt Idx Tr 37.12K 1.15% ▼ 96.04% Apr 30, 2026
7 NT Ext Eq Mkt Idx Fd DC Lending Tier 5 28.41K 0.03% ▲ 0.70% Mar 31, 2026
8 Fidelity Extended Market Index 21.38K 0.66% ▼ 0.36% Apr 30, 2026
9 NT Ext Equity Mkt Index Fund - NL 19.18K 0.02% ▲ 0.00% Mar 31, 2026
10 NT Ext Equity Mkt Idx Fd - DC - NL - T2 15.03K 0.02% ▼ 0.52% Mar 31, 2026

Valuation Metrics

Enterprise Value: $140.42M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $154.49M
EBITDA: $-18.16M
Book Value: $6.64
Earnings/Share: $-4.56
Profit Margin: -59.65%
Operating Margin: -94.32%
ROA (TTM): -46.08%
ROE (TTM): -138.52%
Revenue (TTM): $32.73M
Revenue/Share (TTM): $8.75
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 1,250.60%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 2.74x 0.07x 0.37x -74.29x -0.09x
2024-12-31 1.84x 0.45x 0.46x -52.14x -0.21x
2023-12-31 3.01x 0.31x 0.40x -41.89x -0.25x
2022-12-31 6.68x 0.20x 0.28x -74.56x -0.26x
2021-12-31 5.35x 0.11x 0.21x -25.24x -0.15x
2020-12-31 5.36x 0.06x 0.21x -97.09x -0.11x
2019-12-31 5.24x 0.08x 0.24x -6.51x -0.14x
2018-12-31 6.53x 0.00x 0.25x N/A 0.00x
2017-12-31 12.17x 0.04x 0.08x N/A -0.11x
2016-12-31 14.18x 0.00x 0.07x N/A 0.00x
2015-12-31 19.01x 0.00x 0.05x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CUE.US!